Merck.com - Research and Development News This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Merck’s Investigational Anti-PD-1 Antibody, Pembrolizumab, Under Regulatory Review in Europe for the Treatment of Advanced Melanoma
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the European Medicines Agency (EMA) has accepted for review a Marketing Authorization Application (MAA) for pembrolizumab (MK-3475), the company’s investigational anti-PD-1 antibody, for the treatment of advanced melanoma. If approved by the European Commission (EC), pembrolizumab has the potential to be the first anti-PD-1 therapy in Europe. Language: ...
Source: Merck.com - Research and Development News - June 30, 2014 Category: Pharmaceuticals Tags: Oncology Newsroom Research and Development News Source Type: news

FDA Accepts Merck’s NDA for Fixed-Dose Combination of Raltegravir with Lamivudine
Dateline City: WHITEHOUSE STATION, N.J. If Approved, Fixed-Dose Combination Would Be Used with Other Antiretroviral Agents for the Treatment of HIV-1 in Adults, Adolescents and Certain Pediatric Patients Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the New Drug Application (NDA) for a fixed-dose combination (FDC) of raltegravir with lamivudine for the treatment of HIV-1 infection (MK-0518B) has been accepted for standard review by the U.S. Food and Drug Administrati...
Source: Merck.com - Research and Development News - June 24, 2014 Category: Pharmaceuticals Tags: Research and Development News Source Type: news

Late-Breaking Observational Data Show Patients with Type 2 Diabetes Taking JANUVIA® (sitagliptin) and Metformin Initiated Insulin Therapy at a Slower Rate Compared to Patients Taking a Sulfonylurea and Metformin
In this study, patients treated with a combination of JANUVIA and metformin initiated insulin therapy at a slower rate during the period of observation than patients Language: English read more (Source: Merck.com - Research and Development News)
Source: Merck.com - Research and Development News - June 14, 2014 Category: Pharmaceuticals Tags: Research and Development News Source Type: news

New Post-Hoc Analysis Shows Patients with Type 2 Diabetes Undergoing Intensification of Insulin Therapy Experienced Less Nighttime Hypoglycemia While Being Treated with JANUVIA® (sitagliptin) Compared to Placebo
Dateline City: WHITEHOUSE STATION Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results from a post-hoc analysis showing that patients with type 2 diabetes having treatment intensified with insulin glargine therapy while also being treated with JANUVIA® (sitagliptin) 100 mg once-daily had a lower incidence of nighttime (nocturnal) hypoglycemia compared to patients also receiving placebo. Results were presented at the American Diabetes Association 74th Scientific Sessions. Language: En...
Source: Merck.com - Research and Development News - June 14, 2014 Category: Pharmaceuticals Tags: Research and Development News Source Type: news

First Patient Enrolled in New Phase 3 Trial Program Investigating a Once-Daily Dosing Regimen of ISENTRESS® (raltegravir)
Dateline City: WHITEHOUSE STATION, N.J. ONCEMRK Study Globally Enrolling Treatment-Naïve Adults with HIV-1 WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the first patient has been enrolled in the company’s global Phase 3 clinical trial, ONCEMRK. ONCEMRK is assessing a once-daily investigational formulation of ISENTRESS® (raltegravir), known as reformulated raltegravir, as part of co...
Source: Merck.com - Research and Development News - June 5, 2014 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News Source Type: news

AiCuris and Merck Announce Publication in New England Journal of Medicine of Phase 2 Clinical Trial Results of Investigational Antiviral Agent Letermovir in Bone Marrow Transplant Patients
Dateline City: WUPPERTAL, Germany & WHITEHOUSE STATION, N.J. WUPPERTAL, Germany & WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--AiCuris and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the publication of results from a Phase 2 clinical trial evaluating the safety and efficacy of letermovir, an investigational, oral antiviral agent for the prevention of human cytomegalovirus (CMV) infection in patients receiving bone marrow transplant. Language: English ...
Source: Merck.com - Research and Development News - May 8, 2014 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News Source Type: news

Merck Announces Results from Studies Evaluating Investigational Hepatitis C Treatments, MK-5172 and MK-8742, in Treatment-Naïve Patients with Genotype 1 Infection
Dateline City: WHITEHOUSE STATION, N.J. Clinical Findings Support Advancement into Phase 3 Trials WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced additional data from the ongoing C-WORTHy study, a multi-arm Phase 2 clinical trial evaluating the efficacy and safety of a once-daily, all-oral regimen combining MK-5172, an investigational hepatitis C virus (HCV) NS3/4A protease inhibitor, and M...
Source: Merck.com - Research and Development News - April 10, 2014 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News Source Type: news

Early Findings Exploring the Relationship of PD-L1 Expression and Clinical Outcomes with MK-3475, Merck’s Investigational Anti-PD-1 Immunotherapy, Presented at AACR Annual Meeting 2014
Dateline City: WHITEHOUSE STATION, N.J. Exploratory Analyses in Advanced Melanoma and NSCLC Presented in Oral Session Dr. Roger Perlmutter to Present at AACR Opening Plenary Session WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the presentation of early findings from studies exploring the relationship between tumor PD-L1 expression and clinical outcomes following monotherapy tre...
Source: Merck.com - Research and Development News - April 6, 2014 Category: Pharmaceuticals Tags: Oncology Newsroom Research and Development News Corporate News Latest News Source Type: news

Merck to Present New Data for Investigational Hepatitis C Treatments MK-5172 and MK-8742 at EASL Annual Meeting/The International Liver Congress™ 2014
Dateline City: WHITEHOUSE STATION, N.J. Company to Initiate Phase 3 Clinical Development Program in Q2 2014 WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that new Phase 2 data for its two investigational hepatitis C virus (HCV) treatments - MK-5172, an investigational HCV NS3/4A protease inhibitor, and MK-8742, an investigational HCV NS5A replication complex inhibitor – are scheduled to be...
Source: Merck.com - Research and Development News - March 24, 2014 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News Source Type: news

Merck and Endocyte Announce European CHMP Positive Opinions for VYNFINIT® (vintafolide) and Companion Imaging Agents FOLCEPRI® (etarfolatide) and NEOCEPRI® (Intravenous (IV) folic acid) in Patients with Platinum-Resistant ...
Dateline City: WHITEHOUSE STATION, N.J. & WEST LAFAYETTE, Ind. WHITEHOUSE STATION, N.J. & WEST LAFAYETTE, Ind.--(BUSINESS WIRE)-- Merck and Endocyte Announce European CHMP Positive Opinions for VYNFINIT® (vintafolide) and Companion Imaging Agents FOLCEPRI® (etarfolatide) and NEOCEPRI® (Intravenous (IV) folic acid) in Patients with Platinum-Resistant Ovarian Cancer Language: English Contact: ...
Source: Merck.com - Research and Development News - March 21, 2014 Category: Pharmaceuticals Tags: Oncology Newsroom Research and Development News Corporate News Latest News Source Type: news

Merck’s Investigational Hepatitis C Treatment Regimen MK-5172/MK-8742 Shows Robust Anti-HCV Activity in HIV/HCV Co-Infected Patients with HCV Genotype 1 Infection
Dateline City: BOSTON BOSTON--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced new data from HIV/HCV co-infected patients in the ongoing C-WORTHY Study, a Phase 2 clinical trial evaluating the efficacy and safety of Merck's all-oral, once-daily regimen combining MK-5172, an investigational hepatitis C virus (HCV) NS3/4A protease inhibitor, and MK-8742, an investigational HCV NS5A replication complex inhibitor. Language: English ...
Source: Merck.com - Research and Development News - March 5, 2014 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News Source Type: news

New 96-Week ACTG Study Results Presented at CROI 2014; First Large Study Comparing ISENTRESS® (raltegravir) Regimen to Two Protease Inhibitor Regimens in Previously Untreated Adults with HIV-1
Dateline City: BOSTON BOSTON--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, said today that in a new 96-week, open-label AIDS Clinical Trials Group (ACTG) study designed to compare three different NNRTI-sparing HIV regimens in treatment-naïve patients – one containing Merck’s twice-daily ISENTRESS® (raltegravir) and two containing different once-daily ritonavir-boosted protease inhibitors, atazanavir and darunavir -- all three regimens achieved high and equivalent levels of...
Source: Merck.com - Research and Development News - March 5, 2014 Category: Pharmaceuticals Tags: Research and Development News Source Type: news

Merck’s Investigational HIV Therapy, Doravirine (MK-1439), Demonstrates Antiviral Activity in Phase 2B Study of Treatment-Naïve Adults
Dateline City: BOSTON Merck Plans to Initiate Phase 3 Clinical Development Program in Second Half of 2014 BOSTON--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today presented data from the dose-ranging portion of an ongoing Phase 2B clinical trial of doravirine, the company’s investigational next-generation, non-nucleoside reverse transcriptase inhibitor (NNRTI), at the 21st Conference on Retroviruses and Opportunistic ...
Source: Merck.com - Research and Development News - March 5, 2014 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News Source Type: news

Merck Announces Results from Phase 2b Study of MK-8237, an Investigational House Dust Mite Sublingual Allergen Immunotherapy Tablet
Dateline City: WHITEHOUSE STATION, N.J. Data Presented at the 2014 Annual Meeting of the American Academy of Allergy, Asthma & Immunology (AAAAI) WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced results from a Phase 2b study evaluating two doses of its investigational house dust mite sublingual immunotherapy tablet (MK-8237). The data were presented for the first time during a late-break...
Source: Merck.com - Research and Development News - March 4, 2014 Category: Pharmaceuticals Tags: Research and Development News Latest News Source Type: news